Biology and treatment of basal-like breast cancer

Bingchen Han, William Audeh, Yanli Jin, Sanjay P. Bagaria, Xiaojiang Cui

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Breast cancer is one of the most common cancers identified among women worldwide. It is a heterogeneous disease, with each sub-disease displaying unique clinical and histopathologic characteristics. Based on genomic analysis and gene expression profiling, breast cancer has been classified into several distinct subgroups. Estrogen receptor (ER)-positive breast cancers can be treated with antiestrogen drugs such as tamoxifen, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be treated with HER2-targeted drugs such as trastuzumab. Because of the low expression of ER and HER2, patients with basal-like breast cancer cannot benefit from these targeted therapies. Thus, to identify and validate pivotal theranostic biomarkers for basal-like breast cancer is of paramount importance. This chapter describes the molecular and histological features of basal-like breast cancer as well as the differences between basal-like breast cancer and the other breast cancer subtypes. It presents current progress in identifying the biomarkers for basal-like breast cancer. It concludes with a description of the current therapeutic strategies to treat basal-like breast cancer and argues that inhibition of basal-like tumor-associated signaling pathways, in conjunction with standard therapies, may enhance the treatment efficacy.

Original languageEnglish (US)
Title of host publicationCell and Molecular Biology of Breast Cancer
PublisherHumana Press Inc.
Pages91-109
Number of pages19
Volume9781627036344
ISBN (Print)9781627036344, 1627036334, 9781627036337
DOIs
StatePublished - Jun 1 2013

Fingerprint

Biomarkers
Breast Neoplasms
Estrogen Receptors
Estrogen Receptor Modulators
Tamoxifen
Gene expression
Pharmaceutical Preparations
Tumors
Therapeutics
human ERBB2 protein
Gene Expression Profiling
Neoplasms
Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Han, B., Audeh, W., Jin, Y., Bagaria, S. P., & Cui, X. (2013). Biology and treatment of basal-like breast cancer. In Cell and Molecular Biology of Breast Cancer (Vol. 9781627036344, pp. 91-109). Humana Press Inc.. https://doi.org/10.1007/978-1-62703-634-4_5

Biology and treatment of basal-like breast cancer. / Han, Bingchen; Audeh, William; Jin, Yanli; Bagaria, Sanjay P.; Cui, Xiaojiang.

Cell and Molecular Biology of Breast Cancer. Vol. 9781627036344 Humana Press Inc., 2013. p. 91-109.

Research output: Chapter in Book/Report/Conference proceedingChapter

Han, B, Audeh, W, Jin, Y, Bagaria, SP & Cui, X 2013, Biology and treatment of basal-like breast cancer. in Cell and Molecular Biology of Breast Cancer. vol. 9781627036344, Humana Press Inc., pp. 91-109. https://doi.org/10.1007/978-1-62703-634-4_5
Han B, Audeh W, Jin Y, Bagaria SP, Cui X. Biology and treatment of basal-like breast cancer. In Cell and Molecular Biology of Breast Cancer. Vol. 9781627036344. Humana Press Inc. 2013. p. 91-109 https://doi.org/10.1007/978-1-62703-634-4_5
Han, Bingchen ; Audeh, William ; Jin, Yanli ; Bagaria, Sanjay P. ; Cui, Xiaojiang. / Biology and treatment of basal-like breast cancer. Cell and Molecular Biology of Breast Cancer. Vol. 9781627036344 Humana Press Inc., 2013. pp. 91-109
@inbook{2cfab6522689413897228e6079002ede,
title = "Biology and treatment of basal-like breast cancer",
abstract = "Breast cancer is one of the most common cancers identified among women worldwide. It is a heterogeneous disease, with each sub-disease displaying unique clinical and histopathologic characteristics. Based on genomic analysis and gene expression profiling, breast cancer has been classified into several distinct subgroups. Estrogen receptor (ER)-positive breast cancers can be treated with antiestrogen drugs such as tamoxifen, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be treated with HER2-targeted drugs such as trastuzumab. Because of the low expression of ER and HER2, patients with basal-like breast cancer cannot benefit from these targeted therapies. Thus, to identify and validate pivotal theranostic biomarkers for basal-like breast cancer is of paramount importance. This chapter describes the molecular and histological features of basal-like breast cancer as well as the differences between basal-like breast cancer and the other breast cancer subtypes. It presents current progress in identifying the biomarkers for basal-like breast cancer. It concludes with a description of the current therapeutic strategies to treat basal-like breast cancer and argues that inhibition of basal-like tumor-associated signaling pathways, in conjunction with standard therapies, may enhance the treatment efficacy.",
author = "Bingchen Han and William Audeh and Yanli Jin and Bagaria, {Sanjay P.} and Xiaojiang Cui",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/978-1-62703-634-4_5",
language = "English (US)",
isbn = "9781627036344",
volume = "9781627036344",
pages = "91--109",
booktitle = "Cell and Molecular Biology of Breast Cancer",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Biology and treatment of basal-like breast cancer

AU - Han, Bingchen

AU - Audeh, William

AU - Jin, Yanli

AU - Bagaria, Sanjay P.

AU - Cui, Xiaojiang

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Breast cancer is one of the most common cancers identified among women worldwide. It is a heterogeneous disease, with each sub-disease displaying unique clinical and histopathologic characteristics. Based on genomic analysis and gene expression profiling, breast cancer has been classified into several distinct subgroups. Estrogen receptor (ER)-positive breast cancers can be treated with antiestrogen drugs such as tamoxifen, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be treated with HER2-targeted drugs such as trastuzumab. Because of the low expression of ER and HER2, patients with basal-like breast cancer cannot benefit from these targeted therapies. Thus, to identify and validate pivotal theranostic biomarkers for basal-like breast cancer is of paramount importance. This chapter describes the molecular and histological features of basal-like breast cancer as well as the differences between basal-like breast cancer and the other breast cancer subtypes. It presents current progress in identifying the biomarkers for basal-like breast cancer. It concludes with a description of the current therapeutic strategies to treat basal-like breast cancer and argues that inhibition of basal-like tumor-associated signaling pathways, in conjunction with standard therapies, may enhance the treatment efficacy.

AB - Breast cancer is one of the most common cancers identified among women worldwide. It is a heterogeneous disease, with each sub-disease displaying unique clinical and histopathologic characteristics. Based on genomic analysis and gene expression profiling, breast cancer has been classified into several distinct subgroups. Estrogen receptor (ER)-positive breast cancers can be treated with antiestrogen drugs such as tamoxifen, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be treated with HER2-targeted drugs such as trastuzumab. Because of the low expression of ER and HER2, patients with basal-like breast cancer cannot benefit from these targeted therapies. Thus, to identify and validate pivotal theranostic biomarkers for basal-like breast cancer is of paramount importance. This chapter describes the molecular and histological features of basal-like breast cancer as well as the differences between basal-like breast cancer and the other breast cancer subtypes. It presents current progress in identifying the biomarkers for basal-like breast cancer. It concludes with a description of the current therapeutic strategies to treat basal-like breast cancer and argues that inhibition of basal-like tumor-associated signaling pathways, in conjunction with standard therapies, may enhance the treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84908128106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908128106&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-634-4_5

DO - 10.1007/978-1-62703-634-4_5

M3 - Chapter

AN - SCOPUS:84908128106

SN - 9781627036344

SN - 1627036334

SN - 9781627036337

VL - 9781627036344

SP - 91

EP - 109

BT - Cell and Molecular Biology of Breast Cancer

PB - Humana Press Inc.

ER -